{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Hellgren J"],"pubmed_abstract":["<h4>Background</h4>Early detection of drug-induced liver injury (DILI) during drug development is crucial for reducing drug attrition and ensuring the safety of patients. A versatile, biologically interpretable, and dose-dependent screening approach is therefore needed to inform early stop/go decisions and therapeutic margins.<h4>Methods</h4>We have developed AEGIS (Apoptotic Effector Genes In Safety), a preclinical DILI risk screening and prioritization tool that quantifies dose dependent perturbation of apoptosis-regulating transcription factors from transcriptomics data. We profiled transcriptomic responses after short exposures across primary human hepatocytes (PHH), HepG2/C3A cells, RAW 264.7 cells, and an acute Balb/c mouse study. From these profiles, AEGIS provides quantitative risk"],"journal":["Communications medicine"],"pagination":["48"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12827481"],"repository":["biostudies-literature"],"pubmed_title":["Apoptotic signatures allow early and rapid screening of drug-induced liver injury to accelerate drug discovery."],"pmcid":["PMC12827481"],"pubmed_authors":["Bonetti A","Kalm M","Toki N","Gallon J","Williams DP","Chaudhari A","Chouhan B","Uatay A","Karlsson F","Andersson P","Tan JY","Pryde K","Elgendy R","Lindgren J","Hellgren J","Sagemark J","John B"],"additional_accession":[]},"is_claimable":false,"name":"Apoptotic signatures allow early and rapid screening of drug-induced liver injury to accelerate drug discovery.","description":"<h4>Background</h4>Early detection of drug-induced liver injury (DILI) during drug development is crucial for reducing drug attrition and ensuring the safety of patients. A versatile, biologically interpretable, and dose-dependent screening approach is therefore needed to inform early stop/go decisions and therapeutic margins.<h4>Methods</h4>We have developed AEGIS (Apoptotic Effector Genes In Safety), a preclinical DILI risk screening and prioritization tool that quantifies dose dependent perturbation of apoptosis-regulating transcription factors from transcriptomics data. We profiled transcriptomic responses after short exposures across primary human hepatocytes (PHH), HepG2/C3A cells, RAW 264.7 cells, and an acute Balb/c mouse study. From these profiles, AEGIS provides quantitative risk","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T21:38:31.464Z","creation":"2026-06-05T03:11:35.293Z"},"accession":"S-EPMC12827481","cross_references":{"pubmed":["41444459"],"doi":["10.1038/s43856-025-01306-7"]}}